Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer

Cancer Research

Volumn 63, Issue 13, 2003, Pages 3626-3631

  Nahta, Rita ^a   Trent, Sally ^a   Yang, Chuanwei ^a   Schmidt, Emmett V ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 9; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLAVOPIRIDOL; MESSENGER RNA; PROTEIN; RETINOBLASTOMA PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYCLIN D1 GENE; DRUG POTENTIATION; DRUG TARGETING; ERBB2 GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; FLAVONOIDS; FLOW CYTOMETRY; HUMANS; KINETICS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PIPERIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0037742257     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. McKeage, K., and Perry, C. M. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs, 62: 209-243, 2002.
2. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 103: 211-225, 2000.
3. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire. W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.
4. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., and Shepard, H. M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 89: 4285-4289, 1992.
5. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 344: 783-792, 2001.
6. Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., Sneige, N., Smith, T. L., and Hortobagyi, G. N. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol., 20: 1800-1808, 2002.
7. Lee, R. J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G. K., 3rd, Siegel, P. M., Hung, M. C., Yarden, Y., Horowitz, J. M., Muller, W. J., and Pestell, R. G. Cyclin D1 is required for transformation by activated neu and is induced through an E2F-dependent signaling pathway. Mol. Cell. Biol., 20: 672-683, 2000.
8. Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., and Hynes, N. E. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol., 20: 3210-3223, 2000.
9. Yu, Q., Geng, Y., and Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature (Lond.), 411: 1017-1021, 2001.
10. Sedlacek, H. H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol., 38: 139-170, 2001.
11. Li, Y., Bhuiyan, M., Alhasan, S., Senderowicz, A. M., and Sarkar, F. H. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clin. Cancer Res., 6: 223-229, 2000.
12. Nahta, R., Iglehart, J. D., Kempkes, B., and Schmidt, E. V. Rate-limiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res., 62: 2267-2271, 2002.
13. Price, D. H. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol., 20: 2629-2634, 2000.
14. Peng, J., Zhu, Y., Milton, J. T., and Price, D. H. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev., 12: 755-762, 1998.
15. Chao, S. H., and Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem., 276: 31793-31799, 2001.
16. Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., Wahl, L. M., Harris, E. D., Mikovits, J. A., Monks, A. P., Hollingshead, M. G., Sausville, E. A., and Staudt, L. M. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol., 2: 0041, 2001.
17. Fahraeus, R., Lain, S., Ball, K. L., and Lane, D. P. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene, 16: 587-596, 1998.
18. Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., and Slamon, D. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene, 18: 2241-2251, 1999.
19. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
20. Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA, 95: 14863-14868, 1998.
21. Hanahan, D., and Weinberg, R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000.
22. O'Connor, L., Huang, D. C., O'Reilly, L. A., and Strasser, A. Apoptosis and cell division. Curr. Opin. Cell Biol., 12: 257-263, 2000.
23. Baselga, J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist, 7(Suppl. 4): 2-8, 2002.
24. Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., and Arteaga, C. L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res., 61: 8887-8895, 2001.
25. Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.